Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01621737 · ClinicalTrials.gov registry record · NA
Antipsychotic Effects of Oxytocin
A NA study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT01621737 is a NA study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 42 participants.
The verdict
NCT01621737, a NA study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with antipsychotic medication.
Interventions
- DRUG Placebo
- DRUG Oxytocin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-06 |
| Est. Completion | 2018-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01621737
The ClinicalTrials.gov registry entry for NCT01621737 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01621737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01621737 about?
NCT01621737 is a clinical study titled "Antipsychotic Effects of Oxytocin". The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with antipsychotic medication.
What is the current status of trial NCT01621737?
This trial is currently terminated. It is a NA study. The enrollment target is 42 participants. The study started on 2011-06. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01621737?
The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).
Who is sponsoring clinical trial NCT01621737?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.